Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer

Cancer Research UK (2006) Ovarian cancer incidence statistics. Cancer Research UK. Available from: http://info.cancerresearchuk.org/cancerstats/types/ovary/incidence/index.htm

Horner MJ, Ries LAG, Krapcho M et al (eds) (2009) SEER cancer statistics review, 1975–2006. Available from: http://seer.cancer.gov/csr/1975_2006/

Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249

Marchetti C, Pisano C, Facchini G et al (2009) First-line treatment of advanced ovarian cancer: current research and perspectives. Exp Rev Anticancer Ther 10:47–60

Ozols RF (2006) Challenges for chemotherapy in ovarian cancer. Ann Oncol 17[Suppl 5]:v181–187

Gadducci A, Cosio S, Tana R, Genazzani AR (2009) Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol 69:12–27

Bast RC Jr, Badgwell D, Lu Z et al (2005) New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15[Suppl 3]:274–281

Gupta D, Lis CG (2009) Role of CA125 in predicting ovarian cancer survival: a review of the epidemiological literature. J Ovarian Res 2:13

Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899

Hefler LA, Concin N, Hofstetter G et al (2008) Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 14:710–714

Li AJ, Madden AC, Cass I et al (2004) The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol 92:211–214

Bozkurt N, Yuce K, Basaran M et al (2004) Correlation of platelet count with second-look laparotomy results and disease progression in patients with advanced epithelial ovarian cancer. Obstet Gynecol 103):82–85

Bishara S, Griffin M, Cargill A et al (2008) Pretreatment white blood cell subtypes as prognostic indicators in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 138:71–75

den Ouden M, Ubachs JM, Stoot JE, van Wersch JW (1997) Whole blood cell counts and leucocyte differentials in patients with benign or malignant ovarian tumours. Eur J Obstet Gynecol Reprod Biol 72:73–77

Cho H, Hur HW, Kim SW et al (2009) Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 58:15–23

Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444

Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A (2007) Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 18:171–182

Chen LL, Ye F, Lü WG et al (2009) Evaluation of immune inhibitory cytokine profi les in epithelial ovarian carcinoma. J Obstet Gynaecol Res 35:212–218

Fumagalli LA, Vinke J, Hoff W et al (2003) Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother 26:394–402

Fogar P, Sperti C, Basso D et al (2006) Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 32:22–28

Menczer J, Schejter E, Geva D et al (1998) Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factors and with survival. Eur J Gynaecol Oncol 19:82–84

Gungor T, Kanat-Pektas M, Sucak A, Mollamahmutoglu L (2009) The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors. Arch Gynecol Obstet 279:53–56

Zacharski LR, Memoli VA, Ornstein DL et al (1993) Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. J Natl Cancer Inst 85:1225–1230

Bastida E, Ordinas A, Giardina SL, Jamieson GA (1982) Differentiation of platelet-aggregating effects of human tumor cell lines based on inhibition studies with apyrase, hirudin, and phospholipase. Cancer Res 42:4348–4352

Holmes CE, Levis JE, Ornstein DL (2009) Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis. Clin Exp Metastasis 26:653–661

Aliustaoglu M, Bilici A, Ustaalioglu BB et al (2010) The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment. Med Oncol 27:1060–1065

Ong SL, Garcea G, Thomasset SC et al (2008) Ten-year experience in the management of gallbladder cancer from a single hepatobiliary and pancreatic centre with review of the literature. HPB (Oxford) 10:446–458

Arrieta O, Michel Ortega RM, Villanueva-Rodríguez G et al (2010) Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxelcisplatin chemotherapy: a prospective study. BMC Cancer 10:50

Smith RA, Bosonnet L, Raraty M et al (2009) Preoperative platelet-lymphocyte ratio is an independent signifi cant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 197:466–472